Skip To Main Content

EMICIZUMAB DATA

Quality of Life

The Genentech resources below are patient-friendly summaries of data related to emicizumab and quality of life topics. These patient-friendly summaries include studies with the strongest and most relevant data and are provided only for educational purposes. You are encouraged to discuss any questions you have about your condition and any current or potential treatments with your healthcare provider.

Patient-Friendly Summary

Quality of Life Results With HEMLIBRA in Hemophilia A Without Inhibitors

Patient-Friendly Summary

Quality of Life Results With HEMLIBRA in Hemophilia A With Inhibitors


Select publications and scientific data presentations with the strongest and most relevant data are provided below.

Publication

Pain-Related Quality of Life Outcomes in People With Haemophilia A Receiving Emicizumab: A Post Hoc Analysis of the HAVEN 1, 3 and 4 and STASEY Studies

Hermans C, Skinner MW, Gentile B, et al. Haemophilia. 2025;31:87–98.

Publication

The Effect of Emicizumab Prophylaxis on Health-Related Outcomes in Persons With Haemophilia A With Inhibitors: HAVEN 1 Study.

Oldenburg J, Mahlangu JN, Bujan W, et al. Haemophilia. 2019;25:33–44.

Publication

Health-Related Quality of Life and Caregiver Burden of Emicizumab in Children With Haemophilia A and Factor VIII Inhibitors - Results From the HAVEN 2 Study

Mancuso ME, Mahlangu J, Sidionio R, et al. Haemophilia. 2020;26(6):1009–1018.

Publication

The Effect of Emicizumab Prophylaxis on Long-Term, Self-Reported Physical Health in Persons With Haemophilia A Without Factor VIII Inhibitors in the HAVEN 3 and HAVEN 4 Studies

Skinner MW, Négrier C, Paz-Priel I, et al. Haemophilia. 2021;27:854–865.